

TURKISH ENDOMETRIOSIS & ADENOMYOSIS SOCIETY

ENDOMETRIOSIS BULLETIN • JUNE 2024 • ISSUE XXVIII

15TH ANNIVERSARY MILESTONE • 2009-2024

"One out of every ten women has endometriosis"

FOREWORD

Dear Colleagues,

We are delighted to welcome you to the 28th issue of the Turkish Endometriosis and Adenomyosis Society Bulletin.

The core theme and master title of this newly released issue is designated as "**NEW TREATMENT MODALITIES IN THE MANAGEMENT OF ENDOMETRIOSIS**". Alongside clinical surgical enhancements, pharmacological breakthroughs form the cornerstone of suppressing lesion progression and providing long-term pain relief. In this issue, we present comprehensive and expansive academic summaries of pioneering global articles focused on novel drug developments and specialized molecular target therapies.

Furthermore, this edition features an exceptionally valuable, high-profile scientific literature compilation. You will find meticulously detailed abstracts examining the latest therapeutic agents introduced globally: the utilization of new Oral GnRH antagonists, Vilaprisan as a Selective Progesterone Receptor Modulator (SPRM), the clinical implementation of dopamine agonists, Bazedoxifene combination therapies, targeted Interleukin-33 (IL-33) biological pathways, Prostaglandin E2 Receptor Subtype 4 (hEP4-R) antagonists, and specialized Benzimidazolecarboxylic Acid derivatives.

In addition, this issue records a highly prestigious academic dialog. Op. Dr. Ece Ermin conducted an exclusive and comprehensive interview with the globally acclaimed geneticist and researcher **Dr. Nilüfer Rahmioğlu**. Her insights into the genetic architecture and global epidemiologic mapping of endometriosis represent absolute milestone contributions to our field.

We hope this scientific volume serves as an outstanding, inspiring, and guiding source for our entire medical, pharmaceutical, and academic community.

Best regards,

Executive Board of the Turkish Endometriosis & Adenomyosis Society

FEATURED CONTENT & INNOVATIVE MODALITES

- **Main Theme:** Novel Pharmacological Strategies and Experimental Targeted Pathways.
- **Oral GnRH Antagonists & SPRMs:** Clinical deployment of next-generation oral suppressive molecules including Vilaprisan.
- **Targeted Biological Pathways:** Evaluation of Interleukin-33 (IL-33) inhibition and hEP4-R antagonism in slowing implant vascularization.
- **Exclusive Research Interview:** Dr. Nilüfer Rahmioğlu on the power of genetic-epidemiological multi-center collaborations.

EXCLUSIVE ENDO-EXPERT INTERVIEW PANEL

Interview with Dr. Nilüfer Rahmioğlu (Conducted by Op. Dr. Ece Ermin)

Dr. Ece Ermin: "Do you have any core recommendations and career guidance for our younger colleagues and specialists who are just entering this professional field?"

Dr. Nilüfer Rahmioğlu: "Absolutely. My principal advice to young specialists and professionals starting their careers is to fully utilize and harness the immense power of multidisciplinary research networks. To truly decipher the incredibly complex, heterogeneous, and enigmatic architecture of endometriosis, clinical experience must be systematically integrated with robust genetic and epidemiological studies. Therefore, it is of paramount importance for clinical practitioners to work hand-in-hand with basic scientists and research laboratories. Additionally, regularly participating in and tracking major international scientific platforms—such as the biennial World Congress on Endometriosis—is highly valuable for maintaining immediate access to the most up-to-date global discovery pipelines."

The Endometriosis e-Bulletin is developed periodically by the Turkish Endometriosis & Adenomyosis Society. For scientific inquiries, article submissions, or collaborations, please visit our official communication channels.

Web: www.endometriozisdernegi.org • **Email:** info@endometriozisdernegi.org